Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00345137
Status:
COMPLETED
Last Update Posted:
2006-06-27
First Post:
2006-06-24
Brief Title:
Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
Sponsor:
Regional Hospital Holstebro
Organization:
Regional Hospital Holstebro
Study Overview
Official Title:
Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study tests the hypothesis that systemic and renal nitric oxide availability is changed in polycystic kidney disease and chronic glomerulonephritis
Detailed Description:
In a randomized placebo controlled design the effects of systemic treatment with monomethyl-L-arginine are studied on
1 renal hemodynamics
2 renal sodium excretion and lithium clearance
3 blood pressure and heart rate
4 plasma levels of vasoactive hormones
in patients with adult polycystic kidney disease and chronic glomerulonephrits The results are compared with a group of healthy control subjects
1 renal hemodynamics
2 renal sodium excretion and lithium clearance
3 blood pressure and heart rate
4 plasma levels of vasoactive hormones
in patients with adult polycystic kidney disease and chronic glomerulonephrits The results are compared with a group of healthy control subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None